NCT01718353 - Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

August 31, 2015

Study Completion Date

August 31, 2015

Conditions

Prostate Cancer Metastatic

Interventions

DRUG

DOCETAXEL (XRP6976)

Pharmaceutical form: Concentrate for solution for infusion Route of administration: Intravenous

DRUG

CABAZITAXEL (XRP6258)

Pharmaceutical form: Concentrate and solvent for solution for infusion Route of administration: Intravenous

DRUG

Prednisone

Pharmaceutical form: Tablet Route of administration: Oral

Trial Locations (19)

10021

Investigational Site Number 840001, New York

20817

Investigational Site Number 840007, Bethesda

20850

Investigational Site Number 840017, Rockville

21230

Investigational Site Number 840002, Baltimore

29414

Investigational Site Number 840009, Charleston

46202

Investigational Site Number 840005, Indianapolis

53705

Investigational Site Number 840004, Madison

70006

Investigational Site Number 840025, Metairie

98109

Investigational Site Number 840012, Seattle

35294-3300

Investigational Site Number 840003, Birmingham

20016-2695

Investigational Site Number 840102, Washington D.C.

08003

Investigational Site Number 840010, Cherry Hill

07018

Investigational Site Number 840015, East Orange

10029-6574

Investigational Site Number 840013, New York

T6G 1Z2

Investigational Site Number 124001, Edmonton

H2L 4M1

Investigational Site Number 124004, Montreal

H2W1S6

Investigational Site Number 124002, Montreal

G1R 2J6

Investigational Site Number 124006, Québec

J1H 5N4

Investigational Site Number 124005, Sherbrooke